VIR - CIK 0001706431
The table below shows Vir Biotechnology, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$391.78M | -$446.35M | -$778.78M | $1.66B | -$47.59M | -$190.94M |
| Capital expenditure | $4.83M | $7.30M | $21.57M | $68.01M | $21.82M | $6.55M |
| Investing cash flow | $310.37M | $499.37M | $164.63M | -$1.19B | -$140.81M | -$9.86M |
| Dividends paid | - | - | - | - | - |
Vir Biotechnology, Inc. reported operating cash flow of -$391.78M for fiscal year 2025. That is up 12.2% from -$446.35M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$66.38M (FY 2017) to -$391.78M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $3.79M | $4.39M | $7.48M | $34.76M | $100.33M | $529.47M |